Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

145 Results

Guidelines and Advice

Doxorubicin-Based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

Status: Archived
ID: 11-1
Version: 2

Oct 2014

Guidelines and Advice

The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

Status: Current
ID: GL END 2-31

Jul 2018

Guidelines and Advice

Recommendations for the Safe Use and Handling of Oral Anti-Cancer Drugs (OACDs) in Community Pharmacy: A Pan-Canadian Consensus Guideline

Status: Current
ID: GL-C50-30

Feb 2017

Guidelines and Advice

Guidance on the Substitution of Systemic Therapy Agents

Status: Current
ID: GL-C50-33
Version: 1

Aug 2017

Guidelines and Advice

Pemetrexed Monotherapy for the Maintenance Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Non-Squamous Histology

Status: Archived
ID: CED 21

Jan 2011

Guidelines and Advice

Systemic Therapy in Acute Lymphoblastic Leukemia

Status: Archived
ID: 12-16

Jun 2016

Guidelines and Advice

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Guidelines and Advice

Epirubicin, as a Single Agent or in Combination, for Metastatic Breast Cancer

Status: Archived
ID: 1-6

Sep 2011

Guidelines and Advice

Liposomal Anthracyclines in the Management of HIV-positive Kaposi's Sarcoma

Status: Archived
ID: 12-8
Version: 2

Jun 2013

Guidelines and Advice

Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance and the 2018 Society for Immunotherapy of Cancer Guidance

Status: In-Review
ID: GL END 7-3
Version: 4

Apr 2020

Guidelines and Advice

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Status: Current
ID: GL-END-C50-35

Aug 2023

Guidelines and Advice

Safe Administration of Chemotherapy: Safety During Chemotherapy Ordering, Transcribing, Dispensing, and Patient Identification

Status: In-Review
ID: 12-12-1

Jul 2012

Pages